Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Sufentanil Stories

2014-02-18 08:31:45

CUPERTINO, Calif., Feb. 18, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) In addition, on Monday, March 3, 2014 at 8:10 a.m. Eastern time, James E. Brown, President and...

2013-12-16 08:25:46

- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - REDWOOD CITY, Calif. and AACHEN, Germany, Dec. 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO(TM) (previously known as ARX-01) for potential use in pain treatment within or dispensed by a hospital,...

2013-12-13 08:24:43

- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif., Dec. 13, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today presented additional detail from the Phase 2 dose-finding study...

2013-10-28 16:25:13

CUPERTINO, Calif., Oct. 28, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 4, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2013-10-15 16:22:16

DUBLIN, Ireland, October 15, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lr2fbv/sufentanil_cas) has announced the addition of the "Sufentanil (CAS 56030-54-7) Market Research Report 2013" [http://www.researchandmarkets.com/research/lr2fbv/sufentanil_cas ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Sufentanil (CAS 56030-54-7) Market Research Report 2013...

2013-10-15 08:30:36

First medical meeting data presentations from Phase 3 clinical trial conducted in orthopedic surgery patients REDWOOD CITY, Calif., Oct. 15, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced presentations of its previously reported Phase 3 data for Zalviso(TM) (sufentanil sublingual microtablet system) at...

2013-10-08 08:28:50

Patent estate includes nine issued U.S. patents, nineteen patents worldwide REDWOOD CITY, Calif., Oct. 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 19 issued patents worldwide. These issued patents cover AcelRx's sufentanil...

2013-09-30 08:28:57

Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting REDWOOD CITY, Calif., Sept. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zalviso(TM)...

2013-08-12 16:26:44

REDWOOD CITY, Calif., Aug. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2013. "With the successful completion of our Zalviso(TM) clinical program that includes data from all three Phase 3 studies, each of which met its...

2013-08-05 16:26:53

CUPERTINO, Calif., Aug. 5, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2013. Total revenues were $3.9 million for the three months ended June 30, 2013 as compared to $4.8 million for the three months ended June 30, 2012. Net loss for the three months ended June 30, 2013 was $5.1 million, compared to a net loss of $4.3 million for the same period in 2012. (Logo:...